Stockscreener 앱 받기
326.99
1.75%
-11.08
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Praxis (PRAX) secures $1.4B cash as epilepsy and tremor NDAs advance - Stock Titan
A seizure drug cut monthly seizures 77% as Praxis nears 2 FDA calls - Stock Titan
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results - GlobeNewswire
Praxis earnings up next as biotech nears commercial transformation - Investing.com
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $795 - Moomoo
FMR LLC holds 7.7% of Praxis Precision Medicines (PRAX) — 2.16M shares - Stock Titan
Price-Driven Insight from (PRAX) for Rule-Based Strategy - Stock Traders Daily
Praxis gives 21 new employees stock awards tied to hiring - Stock Titan
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision Medicines Inc expected to post a loss of $3.57 a shareEarnings Preview - TradingView
Praxis Precision Medicines (PRAX.US) will release its earnings report before the market opens on May 7. - Moomoo
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference - The Manila Times
Praxis maps out two investor events in May, starting with Q1 results - Stock Titan
PRAX Stock Price, Quote & Chart | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - ChartMill
Wolfe Research initiates coverage of Praxis Precision Medicines (PRAX) with outperform recommendation - MSN
Praxis (PRAX) Aligns Pay With Ulixacaltamide Progress Is Incentive Design Now a Key Edge? - Yahoo Finance
A Look At Praxis Precision Medicines (PRAX) Valuation After Strong Long Term Shareholder Returns - Yahoo Finance
Praxis (NASDAQ: PRAX) details 2026 virtual meeting, director slate and Say-on-Pay - Stock Titan
Vanguard (NASDAQ: PRAX) reports 1.42M shares, 5.09% stake in Praxis - Stock Titan
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $567 - Moomoo
Analysts Project Growth for Praxis Precision Medicines Biotech Stock - HarianBasis.co
Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide - Insider Monkey
Moody Aldrich Partners LLC Buys New Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Pictet Asset Management Holding SA Makes New $71.09 Million Investment in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines stock drops 2.74% as positive Phase 3 Essential Tremor data shared at AANAM - Traders Union
How Investors May Respond To Praxis (PRAX) Securing Dual FDA Reviews For Key Neurology Drug Candidates - simplywall.st
10 Best Biotech Stocks with Highest Upside Potential - Insider Monkey
Praxis Precision Medicines Prepares for Major FDA Decisions in 2026 - HarianBasis.co
Praxis Precision Medicines Inc. (PRAX): Rare Triple-Catalyst Setup in Neurology - Insider Monkey
M&T Bank Corp Purchases Shares of 12,586 Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Billionaire Joe Edelman’s 5 Stock Picks with Huge Upside Potential - Insider Monkey
Praxis Precision shares rally on price target hikes: Analyst sees upside as high as 100% for stock - MSN
Praxis Precision gains as lead asset accepted for FDA review - MSN
(PRAX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $441 - Moomoo
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Praxis Precision Medicines (PRAX) Projected to Post Earnings on Friday - MarketBeat
Praxis Precision Medicines (PRAX): One of the Best Upside Stocks - Insider Monkey
Praxis rises on elsunersen data for SCN2A encephalopathy in children - MSN
PRAX (Praxis Precision Medicines Inc.) shares rise nearly 7 percent despite wider than expected Q4 2025 per share loss.Stability Report - Cổng thông tin điện tử Tỉnh Sơn La
5 Best Upside Stocks to Buy According to Analysts - Insider Monkey
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $567 - Moomoo
Praxis Precision Medicines (PRAX) Is Up 8.1% After FDA Accepts Ulixacaltamide NDA for Essential Tremor - simplywall.st
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,200 - Moomoo
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $545 - 富途牛牛
Massachusetts Financial Services Co. MA Purchases New Shares in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Truist Financial Remains Bullish on Praxis Precision Medicines (PRAX) - MSN
5.78%
0.81%
자본화:
|
볼륨(24시간):